ARCT (Arcturus Corp) Forward P/S Multiple

Arcturus Therapeutics (ARCT) minimizes the risks of independent distribution through partnerships with industry behemoths and the LUNAR platform, as evidenced by the forward price-to-sales ratio, which stands at 11.20. Transparent management and stringent financial controls ensure stability. Drug development is accelerating via AI and bioreactor automation, although final testing remains the responsibility of physicians.

Arcturus Therapeutics Holdings Inc. - ARCT Forward P/S Multiple (period 07/04/2022 - 11/14/2026)

Summary analytical data breakdowns for Arcturus Corp (ARCT)

- market price and analyst price targets:

Price Chart Arcturus Therapeutics Holdings Inc.|ARCT - Forecast Levels Chart

- business market valuation indicators:

Market Capitalization Arcturus Corp|ARCT - Value Adjusted for Debt and Cash

- issuer book value statistics:

Book Value per Share Arcturus Therapeutics|ARCT - Book Capitalization|Market Value to Book Value Ratio arcturusrx.com|ARCT - Aggregate Asset Value

- debt and solvency information:

- financial results and valuation multiples details:

ARCT - Net Income|Future Profit Arcturus Therapeutics|ARCT - Market Price to Net Income Ratio|Projected Price to Earnings Arcturus Pharma|ARCT - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Arcturus Corp|ARCT - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Arcturus Therapeutics|ARCT - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months arcturusrx.com|ARCT - Expected net earnings per share growth this year|Expected earnings per share growth for next year Arcturus Therapeutics

- total revenue and sales volume data:

ARCT - Company Sales Revenue|Company Future Sales Volume Arcturus Therapeutics Holdings Inc.|ARCT - Market Cap to Sales Volume|Forward P/S Multiple Arcturus Corp

Fundamental company analysis:Arcturus Therapeutics Holdings Inc. ARCT

Investors are assessing fundamental risks through the lens of market value relative to expected earnings. The stability of Arcturus Therapeutics (ARCT) is supported by the neutral status of biomedicine, which minimizes the impact of global conflicts on capitalization. By analyzing the issuer's forward P/S, one can compare the current price with expected annual revenue to identify if the asset is overbought. This indicator helps avoid entering positions at peaks, protecting the portfolio from sharp corrections.

Competitors of Arcturus Therapeutics

Price-to-Projected Revenue Ratio Vertex VRTX|ALNY (Alnylam Pharmaceuticals, Inc.) - Future Price to Revenue|Insmed Inc - Forward P/S Multiple|Forward Price to Sales UTHR (United Therapeutics Inc.)|BMRN: Forward P/S Multiple|bridgebio.com (BBIO) - Forward P/S Multiple|Price-to-Projected Revenue Ratio BGM Group Limited|COGT: Forward Price to Sales|Price-to-Projected Revenue Ratio Xeris Biopharma Inc (XERS)|Forward Price-to-Revenue Multiple Keros Corp KROS|Forward P/S Multiple ETON (Eton Pharmaceuticals)|Forward P/S Multiple kamada.com KMDA|Fulcrum Therapeutics, Inc. - Forward P/S Multiple|ABEO - Forward P/S Multiple|mereobiopharma.com (MREO) - Price-to-Projected Revenue Ratio|Protalix BioTherapeutics, Inc - Forward Price to Sales|PLRX (Pliant Therapeutics Inc) - Forward P/S Multiple|Forward Price-to-Revenue Multiple appliedtherapeutics.com (APLT)|Forward Price-to-Revenue Multiple RNTX (Rein Therapeutics)|Price to Expected Revenue Ratio GELS|Aytu BioPharma - Forward Price-to-Revenue Multiple|Forward P/S Multiple Chemomab Therapeutics Ltd CMMB|SRXH - Price-to-Projected Revenue Ratio|Forward Price to Sales PLRZ (Polyrizon Ltd)|AEZS (zentaris.com) - Forward Price-to-Revenue Multiple|Cyclo Therapeutics Inc. (CYTH) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Inozyme Pharma Inc.|Reneo Pharmaceuticals, Inc (RPHM) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple CSCI (COSCIENS Biopharma Inc.)